<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110874</url>
  </required_header>
  <id_info>
    <org_study_id>HM-FLU-401</org_study_id>
    <nct_id>NCT03110874</nct_id>
  </id_info>
  <brief_title>Clinical Trial on Education Method of Fluterol® Inhalation Inhaler for Asthma Control</brief_title>
  <official_title>A Multi-center, Randomized, Interventional, Open, Phase Ⅳ Clinical Trial on Education Method of Fluterol® Inhalation Capsule 250/50 μg Inhaler for Asthma Control in Patients With Partly Controlled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, open, non-inferiority, Phase 4 study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-center, Randomized, Interventional, Open, Phase Ⅳ Clinical Trial on Education Method
      of Fluterol® Inhalation Capsule 250/50 μg Inhaler for Asthma Control in Patients with Partly
      Controlled Asthma
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2015</start_date>
  <completion_date type="Actual">May 10, 2017</completion_date>
  <primary_completion_date type="Actual">September 1, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in Forced expiratory volume 1 sec (% prediction) at Week 12 from baseline in each group.</measure>
    <time_frame>Week 12</time_frame>
    <description>method of assessment:Forced expiratory volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percent change in Forced expiratory volume 1 sec (% prediction) at Week 4 from baseline in each group.</measure>
    <time_frame>Week 4</time_frame>
    <description>method of assessment:Forced expiratory volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in asthma control (ACT) at Weeks 4 and 12 from baseline in each group.</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>method of assessment: Check list</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inhaler technique score at Weeks 4 and 12 from baseline in each group</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>method of assessment: Check list</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of critical errors at Weeks 4 and 12 in each group.</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>method of assessment: Check list</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with optimal inhaler technique at Weeks 4 and 12 in each group.</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>method of assessment: Check list</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction for the inhalation drug at Weeks 4 and 12 in each group (FSI-10 score).</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>method of assessment: Check list</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence rate (%) at Weeks 4 and 12 in each group.</measure>
    <time_frame>Weeks 4 and 12</time_frame>
    <description>method of assessment: drug administration calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint:AEs(adverse events), vital signs, incidence rate of acute exacerbation.</measure>
    <time_frame>baseline(day1),weeks 4 and weeks12</time_frame>
    <description>occur frequency of adverse events and incidence rate of acute in each group, vital signs: blood pressure and pulse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Experimental group (one-way education)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group (one-way education)
Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)
video based education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group(two-way education)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group(two-way education)
Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)
direct education</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>one-way education</intervention_name>
    <description>'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'</description>
    <arm_group_label>Experimental group (one-way education)</arm_group_label>
    <other_name>video based education</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>two-way education</intervention_name>
    <description>'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'</description>
    <arm_group_label>Control group(two-way education)</arm_group_label>
    <other_name>direct education</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult at the age of 19 or older.

          2. Patient with partially controlled asthma (Asthma Control Test score 16~24)

          3. Written informed consent to study participation.

        Exclusion Criteria:

          1. History of hypersensitivity reactions to the investigational product (Fluterol®) or
             any of its component.

          2. Cardiac tachyarrhythmia.

          3. contreated respiratory fungal, bacterial, or tuberculous infection.

          4. Moderate to severe bronchiectasis

          5. Planned use of the investigational product (Fluterol®) as primary treatment for
             patients with status asthmaticus, patients with an asthmatic crisis*, or patients with
             chronic obstructive pulmonary disease requiring intensive treatment.

               -  Asthmatic crisis: acute exacerbation of asthma meeting at least one of the
                  followings.

               -  Asthma related emergency room visit or hospitalization within 2 weeks prior to
                  screening.

               -  Administration of systemic steroids within 2 weeks prior to screening.

               -  Inhalation of rescue medication at least 10 times/day for the treatment of acute
                  exacerbation of asthmatic symptoms within 2 weeks prior to screening.

          6. Administration of systemic steroids within 2 weeks prior to screening.

          7. Hypersensitivity reactions to lactose and milk.

          8. Pregnant and lactating women or women who are planning to be pregnant or who are
             unwilling to use appropriate methods of contraception during the study.

          9. Previous use of the investigational product (Fluterol®) or a similar inhaler (Onbrez,
             Spiriva) at least once.

         10. Participation in another clinical study for drugs or medical devices to receive the
             investigational product or undergo a procedure using the investigational device within
             4 weeks prior to participation in this study.

         11. Individual considered by the he investigator to be inappropriate for study
             participation due to other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byoung Whui Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

